Kowa boosts US presence with ProEthic buy

 
• By Ian Haydock

Kowa has acquired ProEthic Pharmaceuticals in a move which will jump-start the Japanese firm's commercial presence and independent marketing capability in the US ahead of the planned 2010 launch in this key market of its high cholesterol drug pitavastatin.

Kowa has acquired ProEthic Pharmaceuticals in a move which will jump-start the Japanese firm's commercial presence and independent marketing capability in the US ahead of the planned 2010 launch in this key market of its high cholesterol drug pitavastatin.

Privately held Kowa initially acquired 7.5 million shares in Alabama-based ProEthic, also private, through a third party allotment in April,...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Immunological

More from Therapeutic Category

Gilead’s Yeztugo Gets US Approval For Twice-Yearly PrEP

 
• By Alexandra Shimmings

The first twice-yearly option for HIV prevention has been approved by the US Food and Drug Administration in an advance that “brings us closer than ever to ending the HIV epidemic,” said CEO Daniel O’Day.

ASCO: Pushing The Frontiers Of ADCs

 
• By Mary Jo Laffler

Antibody-drug conjugates are a major part of the oncology pipeline, and data presented at the American Society of Clinical Oncology meeting highlight the emergence of new technologies.

Skyhawk Looks To Soar With Huntington’s Hope

 
• By Kevin Grogan

Oral RNA splicing modulator has gone into a Phase II/III trial